Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 2Phase 1/2 1

Status

Unknown 10Not yet recruiting 6Recruiting 5Completed 5Terminated 2Withdrawn 1Suspended 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1NET 1Gastrointestinal 1Endocrine 1

Conditions

Gastro-enteropancreatic neuroendocrine tumor 1Advanced Solid Tumor 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 144Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Terminated × famitinib × Clear all
NCT05208177 2025-08-22

A Study of SHR-1802 in Patients With Advanced Solid Tumor

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Terminated
25 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT01994213 2019-01-22

A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Terminated
53 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡